NextCure ($NXTC) Rose 260% After Merger Announcement — Scored 100/100 at 6:00 AM ET
NXTC stock rose 260% after announcing a merger with Avere Therapeutics. RTPR scored the release 100/100 at 6:00 AM ET.
NextCure (NASDAQ: NXTC) stock is up today after the company announced a merger with Avere Therapeutics, rising as much as 260% from its price when the release crossed the wire. RTPR assigned the press release (free account required) an impact score of 100/100 at 6:00 AM ET, when the stock traded at $2.97. It later reached an intraday high of $10.68.
What the release announced
According to the press release, NextCure and Avere Therapeutics are combining in an all-stock merger to advance AVR-001, an oral IL-23 therapy designed for once-weekly dosing. The deal includes $320 million in concurrent funding.
What the stock did
Following the announcement, NXTC traded from $2.97 to an intraday high of $10.68, a gain of about 260%.
Historical context
This release received an impact score of 100/100.
- Releases scoring 80-100 produced a 15%+ move 50% of the time.
- Sample size: 122 settled outcomes over the past 90 days.
- Historical observations only, not predictions. Full band-by-band table on the impact scoreboard.
Timeline
- 6:00:00 AM ET — press release crossed the wire
- +171 ms — RTPR delivered the release
- 6:00:19 AM ET — impact score written: 100/100
- $2.97 — price at publication
- $10.68 — intraday high (260% above the price at publication)
Real-time impact scores on every press release are part of RTPR Pro. Impact scores are in beta; historical tendencies, not predictions or investment advice.